news Archives

• 2018-11-15
  news
  NapaJen Pharma, Co., Ltd. initiates Phase 1 study of NJA-730, an RNAi therapeutic with a Unique Delivery Technology
• 2018-05-18
  news
  NapaJen Pharma, Inc. Closes US$1 Million Series B-1 Financing
• 2018-02-09
  news
  NapaJen Pharma Co., Ltd established an Australian subsidiary